Introduction
The process of genome replication that takes place in every mitotic cell cycle has always been considered a topic of "basic research". However, defects in DNA replication can be linked to more than 40 human diseases, including many types of cancer, and probably underlie the process of ageing [1] . DNA replication proteins serve as diagnosis markers of several neoplastic conditions and are the target of widely used antiviral and anticancer drugs. It is time that the connection between DNA replication and human disease is emphasized and its translational aspects explored in more detail.
The main concept behind the control of DNA replication is the classic "replicon hypothesis": specific DNA sequences serve as "origins of replication" and are activated by soluble factors called "initiators". A "replicon" is the stretch of DNA duplicated from a single origin. In this manner, the replication process can be regulated by the frequency of initiation events [2] . The genomes of many viruses, bacteria and Archaea are duplicated in a single replicon, whereas eukaryotic cells contain multiple origins of replication that, saving rare exceptions, are not defined by specific DNA sequences but rather by structural chromatin contexts that remain poorly understood. The overall speed of genome duplication is regulated at different developmental stages by the abundance of initiator proteins and the number of active origins. In addition, DNA replication is carefully coordinated with cell division in order to maintain genomic integrity. Under challenging circumstances, cells use "checkpoint" mechanisms to slow down or arrest DNA replication and also to prevent mitosis when their DNA has been under-replicated, over-replicated or is damaged beyond possible repair. The regulation of eukaryotic DNA replication and its connection to the cellular checkpoints have been extensively reviewed in recent years [3] [4] [5] [6] [7] [8] .
In this review we concentrate on the cellular functions and oncogenic properties of initiator protein CDC6. First, we discuss its biochemical roles in the activation of replication origins and the coordination of S-phase and mitosis.
Then we address the effects of CDC6 overexpression in mammalian cells, recapitulate the known examples of CDC6 deregulation in human cancer and consider different mechanisms that could explain its oncogenicity.
Lessons from the model systems: CDC6 is an essential DNA replication factor.
CDC6 (cell-division cycle 6) was originally identified in a genetic screen aimed at finding mutations that arrested the budding yeast cell cycle [9] . In the pre-genomics era, it took a long time to clone the corresponding gene [10, 11] and to identify its homologues in fission yeast [12] and human cells [13] .
Actually, CDC6 is conserved in every eukaryotic organism, and CDC6-related genes are found in Archaea [14] . The human CDC6 gene is located at chromosome 17q21.3 and its expression is controlled by the E2F/Rb transcription factors that regulate S-phase promoting genes [15] [16] [17] .
The first evidence for the participation of CDC6 in DNA replication stems from the analysis of Cdc6-1, a temperature-sensitive yeast CDC6 mutant which arrested cells at the G1-S transition [18] . CDC6 mutants displayed defects in plasmid maintenance that could be overcome by the addition of extra origins of replication [19] . The expression of CDC6 at the end of mitosis suggested a role of the protein during G1 [20, 21] , which was confirmed using a "conditional KO" yeast strain. Without CDC6, cells rapidly accumulated with a 1C DNA content and could not initiate DNA replication. Remarkably, CDC6-null cells still proceeded to mitosis, indicating a failure in the checkpoint mechanism that prevents cell division in the absence of replication ([20] ; discussed below).
In the early 1990s, a yeast origin of replication was used as a bait to isolate the six-subunit "origin recognition complex" (ORC; [22] Shortly after its identification, it was confirmed that human CDC6 was also essential for initiation of DNA replication. When hCDC6 levels were downregulated in G1 cells by antibody microinjection, cells could not progress into S-phase [15, 17] . Later on, it was found that CDC6 downregulation by RNAi prevented cell proliferation and promoted apoptosis [29, 30] . to influence the specificity with which ORC associates with the DNA [36] . In the presence of ORC and non-origin DNA, CDC6 rapidly hydrolyses ATP and promotes the dissociation of both proteins from the DNA. In contrast, the interaction with specific origin sequences delays ATP hydrolysis, stabilizing the interaction with the DNA until MCM proteins are loaded [37] . Human origins of replication are more complex than their yeast counterparts and it remains to be tested whether the hCDC6 influences the choice of hORC binding sites.
Interestingly, the targeting of hCDC6 to a plasmid is sufficient to create an "artificial" origin of replication, and this capacity depends on an intact ATP binding site [38] .
The second function requiring CDC6 ATPase is the actual loading of MCM proteins. In the current model of pre-RC formation ( Figure 1B) , the hexameric ring formed by MCM proteins, along with their associated factor CDT1, is attracted to the origin by ORC and CDC6, without becoming immediately engaged with the DNA. ATP hydrolysis by CDC6, possibly induced by the interaction with MCM-CDT1, is coupled to the topological association of the MCM ring with the DNA, while CDT1 is released. ORC is also an ATPase whose activity is not required for the loading of the first MCM complex but becomes essential for the repeated loading of additional MCMs. This suggests that CDC6-mediated ATP hydrolysis regulates the effective engagement of MCM with the DNA, whereas ORC-mediated ATP hydrolysis is coupled to the release of each loaded MCM unit from the ORC-CDC6 "loading machine" [39, 40] . The loading of several MCMs at a single origin is not surprising, as they are found on the chromatin in large excess relative to other initiator proteins [41] . The excess MCM complexes are believed to activate "dormant" origins of replication under conditions of replicative stress [42] .
Human CDC6 protein is also capable of ATP binding and hydrolysis, and both can be abolished by mutations in the Walker A/ B motifs [43] . CDC6
protein carrying a Walker A mutation that impairs ATP binding prevented Sphase when it was microinjected in G1 cells, whereas a Walker B mutation that allows ATP binding but impairs hydrolysis allowed the G1-S transition but impaired S-phase progression [43] . An independent study revealed that a mutation in the ATP binding site reduced the ability of CDC6 to cooperate with Cyclin E in the induction of DNA replication in quiescent, serum-starved cells.
This effect was linked to a defective loading of MCM proteins onto the chromatin [44] . Therefore human CDC6, as its yeast counterpart, functions as an ATP-dependent DNA helicase loader prior to DNA replication.
An interesting structural parallelism has been drawn between CDC6 and "clamp loaders" such as RF-C (Replication Factor C) or the γ-complex of E. coli DNA polymerase III [32], multi-subunit complexes that use the energy derived from ATP hydrolysis to engage ring-shaped molecules such as PCNA or the E.
coli β-dimer with the DNA [45, 46] . Similarly, the loading of MCM proteins by CDC6 and ORC could be achieved by a series of conformational changes, coupled to ATP binding and hydrolysis, which open and close the MCM ring around the DNA. Indirect support for this hypothesis comes from the threedimensional map of yeast ORC in complex with CDC6, generated from electron microscopy images [47] . The overall shape and dimensions of the ORC-CDC6
complex match the structure of a ring-shaped archeal MCM complex [48] .
Additional structures of ORC, CDC6 and MCM, ideally in complex with each other, will be required to construct a structural model for the DNA helicase loading reaction.
The only CDC6 high-resolution structure available so far is that of an archaeal homolog [49] . This 2-Å crystallographic structure has revealed at atomic detail the characteristics of the ATP binding domain and has unraveled another interesting structural motif, the WHD (winged-helix domain) that is present in several DNA-binding proteins, including ORC1, the largest subunit of ORC. Mutations in the WHD of fission yeast CDC18 (the CDC6 homolog) impaired the function of the protein in vivo [49] .
Regulation of CDC6 protein in the cell cycle.
In the budding and fission yeasts, the "execution point" of CDC6 goes from late mitosis until late G1, before the activation of the S-phase-promoting cyclindependent kinases (CDKs). In both cases, CDKs phosphorylate CDC6/CDC18, targeting it for ubiquitination and degradation by the proteasome shortly after the formation of pre-RCs [50] [51] [52] [53] [54] . This regulation may be important to avoid origin re-activation within the same cell cycle, and at least in S. pombe the ectopic expression of CDC18 causes DNA re-replication and hyperploidy [55] .
In contrast, CDC6 deregulation does not lead to origin re-activation in S.
cerevisiae, due to overlapping mechanisms that involve the inactivation of additional initiator proteins [56] .
In rapidly proliferating cells, human CDC6 is also destabilized in G1 by the action of the ubiquitin ligase APC Cdh1 and the proteasome [57, 58] , but its steady-state levels increase again before S-phase and remain constant until mitosis [13] . Several studies that made use of epitope-tagged versions of CDC6 converged on the idea that hCDC6 is translocated from the nucleus to the cytosol at the G1-S transition, thereby reducing the risk of origin re-activation [59] [60] [61] . A dissenting note came from other reports that indicated that a fraction of endogenous CDC6 was nuclear and remained associated with the chromatin at all stages of the cell cycle [57, 62, 63] . In a more recent attempt to clarify this issue, it was found that endogenous CDC6 is indeed nuclear throughout the cycle, whereas over-expressed CDC6 may suffer the nuclear-cytosolic translocation [64] . This interesting observation cleared the way to understand the participation of CDC6 in additional cellular functions, including checkpoint mechanisms and mitotic entry (see below).
Although mammalian cells do not eliminate CDC6 in S-phase and G2, it is worth noting that alternative mechanisms have evolved to prevent the untimely formation of pre-RCs. One such mechanism involves ORC1, the largest subunit of the ORC complex, which is inactivated after the G1-S transition either by polyubiquitination by SCF Skp2 and destruction by the proteasome [65] , or by monoubiquitination and dissociation from the chromatin [66] . The "switched regulation" between ORC1 and CDC6 in yeast and mammalian cells may seem surprising, but both proteins are highly related and likely share a common ancestor. Indeed, some Archaeal organisms have a unique ORC1/CDC6 gene that plays the functions of both [14] . Cells also prevent DNA re-replication by exerting a tight control over CDT1, which is essential for MCM loading. CDT1 levels are controlled by proteolytic regulation mediated by SCF Skp2 or the Cul4-DDB1 Cdt2 ubiquitin ligases. In addition, CDT1 activity is controlled by an inhibitor protein called geminin [67] .
Coupling DNA replication and mitosis: CDC6 and the S-M checkpoint.
Checkpoints are signaling pathways that ensure the fidelity of cell division and prevent cell cycle progression when DNA integrity is compromised. The S- kinases and these in turn inactivate CDC25 phosphatase, an essential activator of mitotic kinase CDK1.
Strikingly, both S. cerevisiae and S. pombe CDC6-null cells undergo mitosis after having failed to replicate their DNA [12, 20] . The nature of the signal sent by CDC6 to prevent premature entry into mitosis is independent from the origin-activating role, as a CDC6 mutant that did not support DNA replication still blocked mitosis [34] . Mitotic inhibition by this mutant did not rely on the checkpoint kinase Rad53 (the Chk2 homolog), but it rather involved the inhibition of mitotic CDK through a direct interaction with CDC6 N-terminal domain [68] . Therefore the functions of CDC6 during G1 include an inhibitory action over CDK activity that may facilitate pre-RC formation and prevent mitosis at the same time.
The human cell division cycle is more complex but the potential of human CDC6 to restrain mitosis seems conserved, at least when the protein is overexpressed in G2 cells [69] . In this case the mechanism involves the activation of checkpoint kinase Chk1, because the mitotic block could be involved [70] . Another study done in S. pombe brings us one step closer to an actual mechanism. It was known that CDC18/CDC6 was required to activate the checkpoint kinase Cds1 (Chk2/Rad53) and maintain the block over mitosis in Sphase-arrested cells [71] . Now it has been found that during an S-phase arrest, CDC18/CDC6 is stabilized on the chromatin and serves as a receptor for the Rad3-Rad26 complex, the homologues of mammalian ATR and ATRIP ( Figure   1B ; [72] ). Rad3 and Rad26 are essential to maintain the block on mitosis for the duration of the arrest. Whether this ATR-ATRIP "anchoring" function is conserved in human CDC6 remains to be tested, but it is interesting to note that ATRIP interacts with MCM7 [73] . It could be speculated that chromatin-bound CDC6 attracts MCM7, which in turn recruits ATR-ATRIP to initiate the checkpoint signaling in S-phase-arrested human cells.
The evidence outlined above indicates that CDC6 stabilization mediates the activation of the checkpoint response that prevents mitosis before DNA replication is complete. The fact that the CDKs that drive the main cell cycle transitions are inactivated by the same checkpoint creates a potentially dangerous situation because an excess of CDC6 in the absence of CDK activity could result in origin hyperactivation and DNA overreplication. Actually, in some instances CDC6 protein is downregulated by the cellular responses to DNA damage, probably to prevent further activation of replication origins. CDC6 stability relies on the phosphorylation of three N-terminal serine residues by CDKs, which protects it from ubiquitination and degradation [74, 75] . Therefore, checkpoint responses that inhibit CDK activity are likely to destabilize CDC6.
Indeed, CDC6 levels are reduced after ionizing radiation by a cellular response that involves p53 [74] . Actually, the increase in the number of replicating cells observed after p53 knock-down is reversed by the simultaneous downregulation of CDC6 [74] . Whether a non-degradable form of CDC6 would be sufficient to override the G1-S arrest induced by p53 after DNA damage remains to be tested. p53-independent targeted destruction of CDC6 has also been found after treatment of the cells with adozelesin [76] , methyl methane sulfonate (MMS), or UV irradiation [77] . Degradation of CDC6 by these alternate pathways involves CDC6 ubiquitination by Huwe1, which adds another layer of control on CDC6 protein levels when APC Cdh1 is not active [77] .
Therefore, in a situation of cellular stress, CDC6 is at the crossroads of two seemingly opposing pathways, one that stabilizes it in order to activate the S-M checkpoint signaling and another one that destabilizes it in order to avoid further initiation events ( Figure 1B 
CDC6 in human cancer
Considering the functions of CDC6 in DNA replication and S-M coordination, its deregulation is expected to have a negative impact in genomic integrity. Actually, certain "oncogenic features" can be inferred from experiments carried out in tissue culture cells, i.e. the accelerated G1-S transition observed in G1 nuclei incubated with S-phase extracts supplemented with CDC6 [78] ; the cooperation of CDC6 with Cyclin E to induce DNA replication in quiescent cells [44] ; or the DNA overreplication observed in tumor cells upon ectopic expression of CDC6 and CDT1 [79] . Only in special cases, CDC6 overexpression and stabilization may serve a physiological function, such as the polyploidization of megakaryoblastic cells [80] . adenomas [81] . CDC6 is also overexpressed in approximately 50% of non-small cell lung carcinomas (NSCLC), the most common lung malignancy [82] , and in a subset of mantle cell lymphomas [83] . Interestingly, high levels of CDC6 do not necessarily correlate with increased proliferation within a tumor sample. In the case of NSCLCs, no direct correlation was observed between the levels of CDC6 and proliferation marker Ki67 [82] . Another intriguing observation is that CDC6 is downregulated in aggressive prostate cancer [84] . This could be an in vivo example of a CDC6 loss-of-function situation leading to aberrant cell proliferation.
Because CDC6 and MCM proteins are normally absent in quiescent and differentiated cells, their immunohistochemical detection can be used for the early detection of malignancies. The crisp nuclear signals detected with CDC6
or MCM antibodies in pre-malignant lesions of the cervical squamous epithelium have opened the way for an efficient "immuno-enhanced" Pap smear test [85] .
Additional diagnostic applications based on CDC6 and MCM immunodetection are being developed, including population screenings of bladder, colorectal, anal, lung and oral cancers [86] . In many cases, higher level of replication proteins correlates with poor prognosis [87] . histone deacetylases HDAC1 and HDAC2 that modified the epigenetic signature of the locus, leading to its eventual "heterochomatinization" [89] . This mode of gene repression associated to a neighboring replication origin had an interesting precedent in the control of the yeast mating type locus, which involves the ORC-mediated recruitment of histone deacetylase SIR [90, 91] .
Oncogenic
Is the oncogenic potential of CDC6 exclusively mediated by its effect on the INK4/ARF locus? We believe that this is unlikely, because CDC6 deregulation dramatically affects the cell cycle of model organisms in which these tumor suppressor genes are not conserved. Other mechanisms may apply, starting with the basic functions of CDC6 in DNA replication and Sphase/ mitosis coordination.
Alternative mechanisms of CDC6-driven oncogenesis
The notion that aberrant DNA replication is a driving force of genomic instability is supported by several studies showing, both in yeast and mammalian cells, that the interference with pre-RC formation leads to inefficient S-phase and increases aneuploidy and the frequency of gross chromosomal rearrangements [92] [93] [94] [95] . Therefore, the oncogenic properties of CDC6 could also arise from the genomic instability associated to imperfect DNA replication.
DNA replication stress may be critical at the early stages of tumorigenesis (see Figure 2) . It has been proposed that precancerous cells undergo a transient burst of proliferation in which they lose control over DNA replication, resulting in multiple firing of the same origins and inefficient fork progression [96] . The high frequency of stalled or collapsed replication forks could activate the DNA damage response (DDR) and drive the cells into a senescence state [96, 97] . This cellular response, similar to the premature senescence caused by activation of oncogenes like H-RasV12 [98] , could be a first defense mechanism to avoid proliferation and transformation. In fact, the active forms of ATM and
Chk2 have been detected in a variety of human precancerous lesions [99, 100] .
To explain how origin re-firing could lead to activation of the DDR, it should be noted that DNA re-replication in Xenopus extracts results in the accumulation of multiple "nascent DNA" fragments, likely caused by head-to-tail collision of forks operating on the same DNA template [101] . If this phenomenon also occurred in somatic cells, it could be sufficient to activate the DDR.
Oncogene expression in tissue culture cells seems to activate CDC6, which could be involved in the abnormal DNA replication phase that ensues [96] . At least in one study, CDC6 overexpression in human primary fibroblasts triggered the DDR and drove the cells into senescence [97] . This observation is at odds with the report that CDC6 overexpression represses the INK4/ARF locus and promotes proliferation [89] . The reason for these contrasting results is unclear, but an interesting possibility is that CDC6 overexpression induces a rapid repression of the INK4/ARF locus [89] , facilitating a burst of cell proliferation that could eventually lead to the accumulation of DNA damage and entry into senescence [97] . In this regard, it is worth noting that the repression of the INK4/ARF locus was observed as early as 72h after CDC6 overexpression, whereas the senescence-associated β-GAL assays were performed after a three-week selection for CDC6-expressing cells. A more trivial possibility is that different levels of CDC6 overexpression could tip the balance towards one outcome or the other.
The deregulation of other DNA replication proteins has been linked to cancer in animal models. Overexpression of MCM7 in the basal layer of the epidermis increased the incidence and prevalence of chemically induced papillomas and led to a higher frequency of malignant tumor conversion [102] .
In addition, a genetic screening designed to identify mouse genes implicated in chromosomal instability found a recessive mutation, Chaos3, which turned out to be a viable but hypomorphic mutant of MCM4. Mcm4 Chaos3/Chaos3 embryonic fibroblasts were highly susceptible to chromosome breaks at common fragile sites during replication stress induced by aphidicolin. This effect was accompanied by a very high incidence of spontaneous mammary adenocarcinomas in Mcm4 Chaos3/Chaos3 females [103] . With these precedents, it will be very interesting to evaluate the effects of CDC6 overexpression in vivo (see "Questions for the future" below).
The possible pathways of CDC6-mediated oncogenesis described above do not need to be exclusive. In CDC6-overexpressing NSCLCs, aberrant DNA replication is likely to occur because the MCM-associated factor CDT1 also appears overexpressed in the same set of tumors [82] . On the other hand, a statistically significant inverse correlation between high levels of CDC6 and low levels of p16 INK4a in these tumors suggests that the mechanism of INK4a/ARF repression by CDC6 is also in place [89] .
Questions for the future
The recent discovery of CDC6 oncogenic properties should prompt a effects on four other genes located close to origins of replication, and the preliminary conclusion is that the repressor effect is not universal [89] . A more straightforward approach to this issue will require the analysis of genome-wide expression changes after CDC6 overexpression.
In summary, CDC6 is an essential DNA replication protein that also participates in the activation and maintenance of checkpoints and in some cases affects gene expression. After the remarkable progress of the last twenty years, a new student entering the field may wonder whether there are any mysteries left in CDC6. The answer can be learnt from the inspiring biography of Francis Crick [104] , who "as a small boy was haunted by a fear that by the time he grew up everything would have been discovered". Luckily, his mother came up with a hopeful answer: "Don't worry, ducky. There will be plenty left for you to find out". 
